Arvinas, Pfizer Get FDA Approval for Breast Cancer Treatment
By Elias Schisgall
Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment.
Arvinas said Friday the FDA approved the drug, known generically as vepdegestrant, to treat adults with certain forms of advanced metastatic breast cancer whose disease worsened following at least one line of endocrine therapy.
The approval came ahead of schedule. The FDA had previously targeted a decision by June 5, Arvinas said.
"This milestone demonstrates that targeted protein degradation can translate into meaningful clinical impact," Chief Executive Randy Teel said. "It also strengthens our confidence in the breadth and versatility of our exciting clinical pipeline across oncology, neurodegenerative, and neuromuscular diseases."
The company and Pfizer remain on track to select and announce a third party to bring the treatment option to patients, he said.
Shares of Arvinas were up 3.7% to $10.27. The stock is down 13% this year.
The company said the approval was the FDA's first green light for a Proteolysis Targeting Chimera, or PROTAC, a form of heterobifunctional protein degrader therapy.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
May 01, 2026 13:16 ET (17:16 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States